Last reviewed · How we verify
Investigational varicella vaccine low potency
Investigational varicella vaccine low potency is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | Investigational varicella vaccine low potency |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (PHASE2)
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational varicella vaccine low potency CI brief — competitive landscape report
- Investigational varicella vaccine low potency updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Investigational varicella vaccine low potency
What is Investigational varicella vaccine low potency?
Investigational varicella vaccine low potency is a Biologic drug developed by GlaxoSmithKline.
Who makes Investigational varicella vaccine low potency?
Investigational varicella vaccine low potency is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Investigational varicella vaccine low potency in?
Investigational varicella vaccine low potency is in Phase 2.